Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio osservazionale per raccogliere dati su come Aflibercept (Eylea) somministrato utilizzando un dispositivo di dosaggio pediatrico viene utilizzato nei bambini prematuri affetti da retinopatia della prematurità nel Regno Unito (Regno Unito)

4 novembre 2026 aggiornato da: Bayer

Studio sull'utilizzo del farmaco per Eylea 40 mg/mL utilizzando il dispositivo di dosaggio pediatrico PICLEO in neonati prematuri affetti da retinopatia del prematuro nel Regno Unito

This is an observational study in which only data from babies with retinopathy of prematurity (ROP) who are being treated with aflibercept (Eylea) in prefilled syringe (PFS) using a paediatric dosing device (PDD) are collected and studied.

ROP is a condition that affects the eyes of preterm babies. It occurs when the baby's retina, the part of the eye that senses light, does not develop normally. This may result in vision problems, including blindness, if left untreated. Preterm babies are born before 37 weeks of pregnancy. ROP is more likely to develop in babies who are born before 32 weeks of pregnancy or weigh less than 1.5 kilograms at birth.

Aflibercept is a drug that is injected into the eye. It works by blocking a protein called vascular endothelial growth factor (VEGF) which causes abnormal growth of blood vessels in the retina.

Aflibercept in PFS given using a PDD is approved for the treatment of babies with ROP. The prefilled syringe will be fitted with an injection needle to give aflibercept. And a PDD is a tool used to give the right amount of aflibercept to children in a safe manner.

Since there are other treatments which are commonly used for babies with ROP, the extent of use of aflibercept given using a PDD is unknown.

The main purpose of this study is to:

  • find the number of preterm babies who are treated with aflibercept using a PDD in the UK
  • inform whether this number is enough to perform a study to learn about the long-term safety of aflibercept given using a PDD in babies with ROP

An additional purpose of this study is to describe characteristics including age, sex, and race, and signs and symptoms of ROP observed in babies being treated with aflibercept using a PDD.

The data will come from a database called the National Neonatal Research Database. The study will cover the period from March 2024 to March 2025, if the number of babies found is enough to perform the safety study. If not, data will be collected till April 2027.

In this study only available data from preterm babies born during the study period are collected. No visits or tests are required as part of this study.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Osservativo

Iscrizione (Stimato)

200

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Many Locations, Regno Unito
        • Reclutamento
        • Many locations

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Non più vecchio di 1 anno (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

All premature infants diagnosed with ROP and treated with Eylea PFS + PDD included in the National Neonatal Research Database (NNRD) during the study period in the UK.

Descrizione

Inclusion Criteria:

  • Eligible infants within the NNRD include those who were:

    • 1. Born during the study period, i.e. from Q4/2023 following market introduction of Eylea PFS+PDD and 31st December 2026, and
    • 2. Received care in a neonatal unit that contributes data to the NNRD and the unit has agreed to participate in the study, and
    • 3. Diagnosed with ROP in any stage in at least one eye.

Exclusion Criteria:

  • Infants with missing data for gestational age at birth will be excluded.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: CROSS_SECTIONAL

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Premature infants diagnosed with ROP

Premature infants diagnosed with retinopathy of prematurity (ROP) and treated with aflibercept 0.4 mg using the Eylea 40 mg/mL prefilled syringe (PFS) in combination with the PICLEO paediatric dosing device (PDD) after marketing authorisation in UK and included in the National Neonatal Research Database (NNRD).

Eylea 40 mg/mL solution for injection in pre-filled syringe.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of participants treated with Eylea PFS+PDD upon completion of 1- or 3-years following market introduction
Lasso di tempo: From market introduction of Eylea PFS+PDD in UK up to 3 years
  • To evaluate trends in drug utilization patterns of Eylea prefilled syringe (PFS)+Paediatric Dosing Device (PDD) in the ROP patient population. Exposure to Eylea is defined as a record of Eylea PFS+PDD in the National Neonatal Research Database (NNRD) database during admission to the neonatal unity during the study period.
  • To inform the decision on whether the number of preterm infants with ROP exposed to Eylea PFS+PDD is sufficient (n=200) for proceeding with a cohort study to collect data on long-term safety (ocular and systemic safety including neurodevelopmental outcome).
From market introduction of Eylea PFS+PDD in UK up to 3 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Summary of patient characteristics reported as number of participants with different categories
Lasso di tempo: From market introduction of Eylea PFS+PDD in UK up to 3 years

Birth weight (in categories), sex, gestational age in weeks (in categories), ethnicity, etc.

From market introduction of Eylea PFS+PDD in UK up to 3 years
Summary of maternal factors reported as number of participants with different categories
Lasso di tempo: From market introduction of Eylea PFS+PDD in UK up to 3 years

Problems during pregnancy with mother, problems during pregnancy, mode of delivery, meconium stained liquor at delivery, etc.

From market introduction of Eylea PFS+PDD in UK up to 3 years
Summary of comorbidities reported as number of participants with different categories
Lasso di tempo: From market introduction of Eylea PFS+PDD in UK up to 3 years

Brain injury, necrotising enterocholitis, pulmonary hemorrhage, chronic lung disease, etc.

From market introduction of Eylea PFS+PDD in UK up to 3 years
Summary of clinical condition and resource utilization reported as number of participants with different categories
Lasso di tempo: From market introduction of Eylea PFS+PDD in UK up to 3 years

Respiratory support (mode of ventilation), cardiovascular (inotropic support), feeding (parenteral and enteral nutrition)

From market introduction of Eylea PFS+PDD in UK up to 3 years
Summary of clinical condition and resource utilization reported as days
Lasso di tempo: From market introduction of Eylea PFS+PDD in UK up to 3 years

Intensive care days, invasive ventilation days, parenteral nutrition days

From market introduction of Eylea PFS+PDD in UK up to 3 years
Summary of outcomes of the premature infants reported as number of participants with different categories
Lasso di tempo: From market introduction of Eylea PFS+PDD in UK up to 3 years

Survival to discharge from neonatal care (Y/N); Discharge, death, transferred to another hospital (in categories)

From market introduction of Eylea PFS+PDD in UK up to 3 years
Summary of ocular disease and treatment reported as number of participants with different categories
Lasso di tempo: From market introduction of Eylea PFS+PDD in UK up to 3 years

Number of Eylea injections in the neonatal unity, ROP surgery, ROP stage, ROP clock hours, ROP Max zone, etc.

From market introduction of Eylea PFS+PDD in UK up to 3 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

5 marzo 2024

Completamento primario (Stimato)

31 marzo 2027

Completamento dello studio (Stimato)

30 aprile 2027

Date di iscrizione allo studio

Primo inviato

26 febbraio 2024

Primo inviato che soddisfa i criteri di controllo qualità

11 marzo 2024

Primo Inserito (Effettivo)

18 marzo 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

4 novembre 2026

Ultimo verificato

4 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • 22539

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .